Milestone Asset Management LLC Buys 19,094 Shares of AbbVie Inc. $ABBV

Milestone Asset Management LLC grew its position in AbbVie Inc. (NYSE:ABBV) by 276.4% during the 4th quarter, Holdings Channel reports. The firm owned 26,001 shares of the company’s stock after purchasing an additional 19,094 shares during the quarter. AbbVie makes up about 1.1% of Milestone Asset Management LLC’s investment portfolio, making the stock its 23rd biggest position. Milestone Asset Management LLC’s holdings in AbbVie were worth $5,941,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in ABBV. Chelsea Counsel Co. bought a new position in shares of AbbVie in the third quarter valued at approximately $26,000. Westend Capital Management LLC bought a new stake in AbbVie during the 4th quarter worth approximately $29,000. Texas Capital Bancshares Inc TX acquired a new stake in AbbVie during the 3rd quarter valued at $31,000. WestEnd Advisors LLC increased its holdings in AbbVie by 160.4% during the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares in the last quarter. Finally, Caitlin John LLC bought a new position in AbbVie in the 3rd quarter valued at $33,000. 70.23% of the stock is owned by institutional investors.

AbbVie Trading Down 2.3%

Shares of NYSE:ABBV opened at $200.43 on Thursday. The stock has a market capitalization of $354.39 billion, a P/E ratio of 84.93, a P/E/G ratio of 0.73 and a beta of 0.38. AbbVie Inc. has a 1-year low of $174.40 and a 1-year high of $244.81. The business has a 50-day moving average price of $217.87 and a two-hundred day moving average price of $222.77.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter last year, the firm earned $2.16 EPS. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities analysts predict that AbbVie Inc. will post 14.22 EPS for the current year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.5%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Insiders Place Their Bets

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. 0.06% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of recent analyst reports. The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 price objective on shares of AbbVie in a research note on Wednesday, January 28th. Citigroup cut their price target on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a report on Tuesday, January 27th. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Guggenheim increased their price objective on shares of AbbVie from $242.00 to $249.00 and gave the stock a “buy” rating in a report on Friday, April 10th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $253.19.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Canaccord initiated coverage with a Buy/strong-buy and a $262 price target (implies ~29% upside), signaling Wall Street confidence in AbbVie’s multi-franchise growth profile and boosting investor demand. Canaccord Calls AbbVie a Core Holding With a $262 Target
• Positive Sentiment: AbbVie announced a $1.4 billion, 185‑acre manufacturing campus in Durham, NC — its largest single-site investment — expanding AI-enabled production capacity for immunology, neuroscience and oncology drugs and creating ~734 permanent jobs. This strengthens supply chain control and supports future volume growth. AbbVie to build $1.4 billion manufacturing campus in North Carolina
• Positive Sentiment: AbbVie struck an exclusive licensing deal with Haisco Pharmaceutical Group to develop, manufacture and commercialize novel pain medicines — a potential pipeline expansion and commercialization pathway that could add new revenue streams if assets advance. AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development
• Positive Sentiment: Late-breaking Phase 2 data for AbbVie’s ADC mirvetuximab (ELAHERE) and the Durham AI plant narrative have been highlighted as factors that could reframe the bull case — suggesting improving oncology prospects alongside manufacturing-led efficiency gains. These developments underpin bullish commentary in several outlets. Does AbbVie’s Durham AI Plant and Ovarian Cancer Data Reframe the Bull Case for ABBV?
• Neutral Sentiment: General market write-ups and “best stock on a pullback” lists are circulating, which can attract retail interest but typically have limited immediate impact beyond amplifying existing momentum. AbbVie (ABBV): The Best Stock to Buy on a Pullback
• Negative Sentiment: Analyst caution ahead of next earnings: Zacks and some preview pieces note AbbVie may lack the setup for a clear earnings beat next quarter — a reminder that upcoming results and guidance could pressure the stock if they disappoint. AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.